GFAP and astrocytoma (excluding glioblastoma): As these variants, as shown for GFAPδ, differentially correlate to the malignancy of the tumor, the current use of commercial GFAP antibodies that recognize all isoforms most likely masks a consistent correlation of GFAP to astrocytoma malignancy grade.